CA
GSK icon

CoreCap Advisors’s GSK GSK Stock Holding History

CoreCap Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$156K Sell
2,975
-125
-4% -$6.61K ﹤0.01% 941
2026
Q1 		$171K Sell
3,100
-30
-1% -$1.63K 0.01% 851
2025
Q4 		$153K Buy
3,130
+121
+4% +$5.64K 0.01% 877
2025
Q3 		$130K Sell
3,009
-131
-4% -$5.12K ﹤0.01% 946
2025
Q2 		$121K Buy
3,140
+338
+12% +$12.9K ﹤0.01% 921
2025
Q1 		$109K Buy
2,802
+717
+34% +$26.2K ﹤0.01% 875
2024
Q4 		$70.5K Buy
2,085
+104
+5% +$3.74K ﹤0.01% 1046
2024
Q3 		$81K Sell
1,981
-573
-22% -$23.4K ﹤0.01% 1004
2024
Q2 		$98.3K Buy
2,554
+481
+23% +$20.2K 0.01% 505
2024
Q1 		$88.9K Buy
+2,073
New +$85.5K ﹤0.01% 880
2022
Q4 		$70.1K Buy
+1,996
New +$66.5K 0.01% 865
2022
Q3 		– Sell
-1,203
Closed -$66K – 1154
2022
Q2 		$66K Buy
+1,203
New +$66.4K 0.01% 847
2022
Q1 		– Sell
-1,992
Closed -$110K – 1155
2021
Q4 		$110K Buy
+1,992
New +$104K 0.01% 720

Other funds holding GSK

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
FVWA
Foster Victor Wealth Advisors Greenville, South Carolina $1.9B AUM 24.46% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
KFP
Keystone Financial Planning Cleveland, Ohio $388M AUM 16.66% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

CoreCap Advisors's GSK Position: Q2 2026 in Review

CoreCap Advisors reduced its GSK (GSK) stake by 4% in Q2 2026, selling an estimated $6.61K and leaving 2,975 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #941.

CoreCap Advisors first reported a position in GSK in Q4 2021 and has held it in 13 quarters since. The position peaked at $171K in Q1 2026. 235 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • CoreCap Advisors held 2,975 shares of GSK worth $156K as of Q2 2026.
  • CoreCap Advisors sold 125 GSK shares in Q2 2026, an estimated $6.61K.
  • GSK made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #941 holding.
  • CoreCap Advisors first reported a position in GSK in Q4 2021 and has held it in 13 quarters since.
  • CoreCap Advisors's GSK position peaked at $171K in Q1 2026.
  • 235 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.